Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Lakartidningen
|
December 14, 2016
[The new cancer drugs should be administered with individualized dosage]
Curt Peterson, Henrik Lövborg
BMC Research Notes
|
July 1, 2009
Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
Henrik Lövborg, Robert Burman, Joachim Gullbo
Molecular Cancer Therapeutics
|
May 14, 2004
Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828
Henrik Lövborg, Peter Nygren, Rolf Larsson
BMC Pharmacology & Toxicology
|
June 11, 2014
Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system
Henrik Lövborg, Mikael Holmlund, Staffan Hägg
Anti-Cancer Drugs
|
June 3, 2005
Screening for apoptosis--classical and emerging techniques
Henrik Lövborg, Joachim Gullbo, Rolf Larsson
Lakartidningen
|
December 17, 2009
[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value]
Henrik Lövborg, Ingela Jacobsson, Staffan Hägg
Current Drug Safety
|
June 6, 2012
A fatal outcome after unintentional overdosing of rivastigmine patches
Henrik Lövborg, Anna K Jönsson, Staffan Hägg
Journal of Biomolecular Screening
|
January 9, 2007
Image-based screening for the identification of novel proteasome inhibitors
Linda Rickardson, Malin Wickström, Rolf Larsson, et al.
Cancer Research
|
August 3, 2002
Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1
Henrik Lövborg, Jacek Wojciechowski, Rolf Larsson, et al.
International Journal of Environmental Research and Public Health
|
July 25, 2017
Increased Risk of Drug-Induced Hyponatremia during High Temperatures
Anna K Jönsson, Henrik Lövborg, Wolfgang Lohr, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Lakartidningen
|
December 14, 2016
[The new cancer drugs should be administered with individualized dosage]
Curt Peterson, Henrik Lövborg
BMC Research Notes
|
July 1, 2009
Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
Henrik Lövborg, Robert Burman, Joachim Gullbo
Molecular Cancer Therapeutics
|
May 14, 2004
Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828
Henrik Lövborg, Peter Nygren, Rolf Larsson
BMC Pharmacology & Toxicology
|
June 11, 2014
Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system
Henrik Lövborg, Mikael Holmlund, Staffan Hägg
Anti-Cancer Drugs
|
June 3, 2005
Screening for apoptosis--classical and emerging techniques
Henrik Lövborg, Joachim Gullbo, Rolf Larsson
Lakartidningen
|
December 17, 2009
[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value]
Henrik Lövborg, Ingela Jacobsson, Staffan Hägg
Current Drug Safety
|
June 6, 2012
A fatal outcome after unintentional overdosing of rivastigmine patches
Henrik Lövborg, Anna K Jönsson, Staffan Hägg
Journal of Biomolecular Screening
|
January 9, 2007
Image-based screening for the identification of novel proteasome inhibitors
Linda Rickardson, Malin Wickström, Rolf Larsson, et al.
Cancer Research
|
August 3, 2002
Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1
Henrik Lövborg, Jacek Wojciechowski, Rolf Larsson, et al.
International Journal of Environmental Research and Public Health
|
July 25, 2017
Increased Risk of Drug-Induced Hyponatremia during High Temperatures
Anna K Jönsson, Henrik Lövborg, Wolfgang Lohr, et al.
Page
of 3